Therapeutic Target Details
| Target ID: | T21 |
| Target Name: | Diacylglycerol O-acyltransferase 2 |
| Synonyms: | DGAT2; Acyl-CoA retinol O-fatty-acyltransferase; ARAT; Diglyceride acyltransferase 2; Retinol O-fatty-acyltransferase |
| GENE: | DGAT2 |
| Action: | inhibitor |
| Class: | Enzyme |
| UniProtKB ID: | Q96PD7 |
| Entry Name: | DGAT2_HUMAN |
| Related Drugs: | IONIS-DGAT2rx |
| Mechanism: | The final step in triglyceride synthesis, esterifying a fatty acyl-CoA moiety to diacylglycerol, is catalysed by diacylglycerol acyltransferase (DGAT). Two isoforms of this enzyme have been identified, DGAT1 and DGAT2, which have distinct patterns of expression and substrate specificity. |
| Reference (PMIDs): | 18757836 |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B095499 | CHEMBL1766811 | Small molecule | -- | 569.58 | C30H30F3N3O5 | ACID | Details |
| B096651 | CHEMBL1835919 | Small molecule | PF-04620110 | 396.45 | C21H24N4O4 | ACID | Details |
| B105991 | CHEMBL1939473 | Small molecule | -- | 382.45 | C19H18N4O3S | ACID | Details |
| B106205 | CHEMBL1952025 | Small molecule | -- | 380.45 | C21H24N4O3 | ACID | Details |
| B108757 | CHEMBL2036567 | Small molecule | -- | 383.38 | C19H18FN5O3 | ACID | Details |
| B108759 | CHEMBL2036730 | Small molecule | -- | 456.45 | C23H22F2N4O4 | ACID | Details |
| B109100 | CHEMBL2063278 | Small molecule | -- | 350.21 | C16H13Cl2N3O2 | NEUTRAL | Details |
| B114367 | CHEMBL2165819 | Small molecule | -- | 350.42 | C20H22N4O2 | ACID | Details |
| B114441 | CHEMBL2178953 | Small molecule | -- | 367.45 | C21H25N3O3 | ACID | Details |
| B115602 | CHEMBL2334082 | Small molecule | -- | 523.59 | C31H29N3O5 | ACID | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01360 | 34774753 | Mol Ther | An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. | Details |
| A05608 | 33190588 | Autophagy | TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. | Details |
| A07295 | 32553151 | Lancet Gastroenterol Hepatol | Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. | Details |
| A10144 | 31470288 | Nutr Res | Gnotobiotic mice inoculated with Firmicutes, but not Bacteroidetes, deteriorate nonalcoholic fatty liver disease severity by modulating hepatic lipid metabolism. | Details |
| A19224 | 26693162 | J Diabetes Metab Disord | The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease. | Details |
| A47035 | 28689299 | J Mol Med (Berl) | 4-O'-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice. | Details |